Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

11 , 12 No randomized phase III study neither compared FOLFIRINOX versus GEM-NAB directly, but retrospective studies showed a trend toward greater OS in patients treated with FOLFIRINOX. 13 , 14 Recently, the first results of NALIRIFOX versus GEM-NAB, presented during ASCO congress, reported OS in favor of NALIRIFOX. 15 These data are opposed to other phase III recent trial, stopped for futility, showing a signal in favor of GEM-NAB over FOLFIRINOX regimen. 16 These data do not argue for a reimbursement of GEM-NAB in first line in France.
Additionally, patients with OI with AD inheritance showed a trend toward higher percentage increases in aBMD at the LS (3.18 ± 4.38% vs 0.29 ± 5.19%), FN (2.25 ± 6.31% vs 0.56 ± 14.49%), and TH (3.15 ± 6.31% vs 2.59 ± 6.46%), along with a trend toward a greater decrease in β-CTX levels (−54.87 ± 27.56% vs −21.86 ± 48.38%) than those with non-AD inheritance, although this did not reach statistical significance.